Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial is a research paper published in PLOS Global Public Health (2024). On theSindex it has a DataRank of 0.108. It has been cited 1 time, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
4.34 × 10⁻³
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 1 citer.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI068614
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI068618
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI068635
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI069453
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI069519
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI069422
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI064518
Bill and Melinda Gates Foundation
Grant: OPP1110792
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: HHSN272201300033C//HHSN272201600012C
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: UM1 AI068618
NIAID NIH HHS
Grant: UM1 AI154463
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 5P30AI064518-17
Centers for AIDS Research (CFAR)
National Institutes of Health
Grant: 5UM1AI069422-13
South African Medical Research Council Clinical Trials Unit (MRC CTU)
National Institutes of Health
Grant: 4UM1AI069453-07
Soweto Clinical Trials Unit
National Institutes of Health
Grant: 5UM1AI069519-16
HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027
National Institutes of Health
Grant: 5UM1AI069469-10
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
FWCI
0.24
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals